I'm LongbridgeAI, I can summarize articles.Fosun International has filed for the spin-off listing of its subsidiary, Fosun Adgenvax, on Hong Kong’s Main Board. The IPO application was submitted on June 26, 2026, for H shares. The offering size is expected to be up to 25% of the enlarged share capital, with a 15% over-allotment option. Fosun Adgenvax will remain under Fosun Pharma post-listing, and preferential allocation is planned for Fosun International shareholders, subject to regulatory approvals.
- Fosun International filed for a spin-off listing of Fosun Adgenvax, a Fosun Pharma subsidiary, on Hong Kong’s Main Board. * Fosun Adgenvax submitted its listing application on June 26, 2026 for listing and dealing in its H shares. * IPO size is expected to be up to 25% of enlarged share capital, with a 15% over-allotment option. * Fosun Adgenvax is expected to remain a Fosun Pharma unit following the listing. * Preferential allocation for Fosun International shareholders is planned, subject to regulatory clearances including the CSRC and Hong Kong Exchange. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260626-12218048), on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)